文献速递技术与安全泌尿生殖CT

床旁肌酐检测用于对比增强CT前肾功能评估的成本效益

Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging.
PubMed 文献 · Eur J Radiol · 2021-07-27

结果显示,风险因素问卷筛查阳性者行i-STAT床旁检测、阳性者再行实验室确认检测的序列策略最具成本效益,净健康获益9.98 QALYs,成本效益概率79.3%,较现行实践增量净健康获益0.004 QALYs。作者认为该策略的成本效益主要源于减少CECT路径中的延误。

要点

  • 风险因素筛查+床旁肌酐检测+实验室确认的序列策略最具成本效益。
  • 该策略净健康获益9.98 QALYs,成本效益概率79.3%。
  • 成本效益主要来自减少CECT路径中的延误。

核心结论

  • 风险因素问卷、床旁检测和实验室确认检测相结合的检测序列与现行实践相比似乎具有成本效益。
  • 床旁检测的成本效益似乎由减少CECT路径中的延误所驱动。
  • 静脉对比剂导致急性肾损伤的贡献以及静脉水化的获益与危害仍不确定。

研究设计与样本

  • 研究为决策树模型分析,表征诊断路径和患者管理(如静脉水化)并链接至静脉对比剂相关不良肾脏事件。
  • 床旁设备的诊断准确性来自系统综述和meta分析;其他参数来自相关文献来源和数据库。
  • 从医疗保健角度基于最高净健康获益(NHB)确定成本效益策略,NHB以质量调整生命年(QALYs)表示,阈值为£20,000/QALY。

诊断标准与关键数值

  • 成本效益策略为:筛查所有个体风险因素,对筛查阳性者行床旁检测(i-STAT),对床旁检测阳性者行确认性实验室检测。
  • 该策略NHB为9.98 QALYs,具有成本效益的概率为79.3%。
  • 与现行实践(确认性实验室检测)相比,该策略的增量NHB为0.004 QALYs。
  • 结果对情景分析总体稳健。

临床应用与阅片要点

  • 在非急诊门诊CECT前,可考虑先以风险因素问卷筛查,阳性者行床旁肌酐检测,再对床旁阳性者行实验室确认。
  • 该序列策略可能减少CECT路径中的延误,从而提升成本效益。
  • 静脉对比剂相关急性肾损伤的贡献及静脉水化的获益与危害尚不确定,临床决策时需注意。

局限性

  • 静脉对比剂导致急性肾损伤的贡献以及静脉水化的获益与危害仍不确定。
  • 床旁设备诊断准确性来自系统综述和meta分析,其他参数来自文献和数据库,模型结果依赖于这些来源的假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Patients undergoing contrast-enhanced computed tomography (CECT) imaging in a non-emergency outpatient setting often lack a recent estimated Glomerular Filtration Rate measurement. This may lead to inefficiencies in the CECT pathway. The use of point-of-care (POC) creatinine tests to evaluate kidney function in these patients may provide a safe and cost-effective alternative to current practice, as these can provide results within the same CECT appointment.

METHODS: A decision tree model was developed to characterise the diagnostic pathway and patient management (e.g., intravenous hydration) and link these to adverse renal events associated with intravenous contrast media. Twelve diagnostic strategies including three POC devices (i-STAT, ABL800 Flex and StatSensor), risk factor screening and laboratory testing were compared with current practice. The diagnostic accuracy of POC devices was derived from a systematic review and meta-analysis; relevant literature sources and databases informed other parameters. The cost-effective strategy from a health care perspective was identified based on highest net health benefit (NHB) which were expressed in quality-adjusted life years (QALYs) at £20,000/QALY.

RESULTS: The cost-effective strategy, with a NHB of 9.98 QALYs and a probability of being cost-effective of 79.3%, was identified in our analysis to be a testing sequence involving screening all individuals for risk factors, POC testing (with i-STAT) on those screening positive, and performing a confirmatory laboratory test for individuals with a positive POC result. The incremental NHB of this strategy compared to current practice, confirmatory laboratory test, is 0.004 QALYs. Results were generally robust to scenario analysis.

CONCLUSIONS: A testing sequence combining a risk factor questionnaire, POC test and confirmatory laboratory testing appears to be cost-effective compared to current practice. The cost-effectiveness of POC testing appears to be driven by reduced delays within the CECT pathway. The contribution of intravenous contrast media to acute kidney injury, and the benefits and harms of intravenous hydration remain uncertain.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Duarte A, Walker S, Altunkaya J, et al. Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging. Eur J Radiol. 2021. PMID: 34339953. doi:10.1016/j.ejrad.2021.109872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。